Prospective, multicenter, randomized, double-blind, placebo-controlled, efficacy and safety clinical trial with subcutaneous immunotherapy in patients with rhinitis/rhinoconjunctivitis with or without mild to moderate asthma sensitized to Dermatophagoides pteronyssinus and/or Dermatophagoides farinae

This research study is looking into a new way to treat common allergies, specifically those caused by dust mites. Many people in the UK suffer from allergic rhinitis, often known as hay fever, which can cause sneezing, a runny nose, itchy eyes, and generally make you feel quite unwell. Some people with these allergies also have asthma that is mild or moderate and can be managed with current treatments. This study is trying to find an 'aetiological' treatment, which means it aims to address the root cause of the allergy, not just the symptoms.

The treatment being tested is called 'Clustoid MM09' and it's a type of immunotherapy. This kind of treatment works by gradually training your immune system to be less reactive to the things that trigger your allergies, like dust mites. It's given as an injection under the skin. Half of the participants in the study will receive this active treatment, while the other half will receive a placebo, which looks identical but doesn't contain the active ingredient. This is a common and important way to fairly test if the new treatment really makes a difference.

The main goal of the study is to see if Clustoid MM09 can effectively reduce the symptoms of hay fever and asthma, and if people need to take less allergy medication as a result. Researchers will compare how people feel at the start of the study to how they feel at the end. They'll also be carefully checking for any side effects to make sure the treatment is safe.